Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 27;12(5):760.
doi: 10.3390/cells12050760.

Human Bone Marrow-Derived Mesenchymal Stromal Cells Reduce the Severity of Experimental Necrotizing Enterocolitis in a Concentration-Dependent Manner

Affiliations

Human Bone Marrow-Derived Mesenchymal Stromal Cells Reduce the Severity of Experimental Necrotizing Enterocolitis in a Concentration-Dependent Manner

Livia Provitera et al. Cells. .

Abstract

Necrotizing enterocolitis (NEC) is a devastating gut disease in preterm neonates. In NEC animal models, mesenchymal stromal cells (MSCs) administration has reduced the incidence and severity of NEC. We developed and characterized a novel mouse model of NEC to evaluate the effect of human bone marrow-derived MSCs (hBM-MSCs) in tissue regeneration and epithelial gut repair. NEC was induced in C57BL/6 mouse pups at postnatal days (PND) 3-6 by (A) gavage feeding term infant formula, (B) hypoxia/hypothermia, and (C) lipopolysaccharide. Intraperitoneal injections of PBS or two hBM-MSCs doses (0.5 × 106 or 1 × 106) were given on PND2. At PND 6, we harvested intestine samples from all groups. The NEC group showed an incidence of NEC of 50% compared with controls (p < 0.001). Severity of bowel damage was reduced by hBM-MSCs compared to the PBS-treated NEC group in a concentration-dependent manner, with hBM-MSCs (1 × 106) inducing a NEC incidence reduction of up to 0% (p < 0.001). We showed that hBM-MSCs enhanced intestinal cell survival, preserving intestinal barrier integrity and decreasing mucosal inflammation and apoptosis. In conclusion, we established a novel NEC animal model and demonstrated that hBM-MSCs administration reduced the NEC incidence and severity in a concentration-dependent manner, enhancing intestinal barrier integrity.

Keywords: apoptosis; caspase 3; human bone marrow mesenchymal stromal cells; inflammation; interleukin 1b; mouse model; necrotizing enterocolitis; neonate; zonula occludens-1.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Timeline of NEC induction protocol. NEC, necrotizing enterocolitis; PBS, phosphate-buffered saline; hBM-MSCs, human bone marrow-derived mesenchymal stromal cells; LPS, lipopolysaccharide; i.p., intraperitoneal.
Figure 2
Figure 2
Histological grading of NEC severity in a NEC neonatal mouse model. Pups were subjected to NEC induction protocol and euthanized after 72 h or earlier in case of distress symptoms. Intestines were harvested, fixed in 10% formalin, and stained with hematoxylin–eosin. The severity of experimental NEC was classified from 0 to 4 according to a previously validated scoring system [66], as follows: (A) grade 0: intact villi; (B) grade 1: superficial epithelial cell sloughing; (C) grade 2: partially compromised villi structure, basal cells still present; (D) grade 3: complete villous necrosis, with basal cells still appreciable; (E) grade 4: transmural necrosis, basal membrane destroyed. Samples with histological scores of 2 or higher were considered positive for NEC. An injury score of 3 or 4 defines severe NEC. NEC: necrotizing enterocolitis. Image magnification 100×.
Figure 3
Figure 3
Term infant formula feedings, hypoxic–ischemic insults, and enteral LPS administration induced NEC in a neonatal mouse model. (A) NEC histological grading and incidence in control (n = 16) and NEC (n = 26) groups. (B) Representative histological sections from each group (hematoxylin/eosin staining). Image magnification: upper panels, 40×; lower panels, 100×. LPS: lipopolysaccharide; NEC: necrotizing enterocolitis. *** p ≤ 0.001 (Fisher’s exact test).
Figure 4
Figure 4
hBM-MSCs reduced NEC incidence and severity in a concentration-dependent manner in a neonatal mouse NEC model. (A) NEC incidence in all the experimental groups based on NEC histological grade (Control, n = 16; NEC + PBS, n = 15; NEC + hBM-MSCs (0.5 × 106), n = 23; NEC + hBM-MSCs (1 × 106), n = 15). (Control vs. NEC + PBS; NEC + PBS vs. NEC + hBM-MSCs (1 × 106); NEC + hBM-MSCs (0.5 × 106) vs. NEC + hBM-MSCs (1 × 106)). (B) Representative histological sections from each treatment group (hematoxylin/eosin staining). Image magnification: upper panels, 40×; lower panels, 100×. hBM-MSCs: human bone marrow-derived mesenchymal stromal cells; NEC: necrotizing enterocolitis; PBS: phosphate-buffered saline. *** p < 0.001 (Fisher’s Exact test).
Figure 5
Figure 5
hBM-MSCs reduced apoptosis and stimulated tissue regeneration in a neonatal mouse NEC model. (A) Representative Caspase-3 staining on histological intestinal sections from mice belonging to the NEC + PBS and NEC + hBM-MSCs (1 × 106) experimental groups. Scale bar: 100 µm. (B,C) Representative Ki67 staining and its relative quantification on histological intestinal sections from mice belonging to the NEC + PBS and NEC + hBM-MSCs (1 × 106) experimental groups (n = 5) Scale bar: 200 µm. (D) Relative gene expression of the anti-apoptotic gene Bcl2 and the pro-inflammatory cytokine IL-1B. (E) Relative gene expression of the tight junction component ZO-1 in the four indicated experimental groups. Bcl2: B-cell lymphoma 2; hBM-MSCs: human bone marrow-derived mesenchymal stromal cells; IL-1B: Interleukin 1b; NEC: necrotizing enterocolitis; PBS: phosphate-buffered saline; ZO-1: zonula occludens-1. * p < 0.05; ** p < 0.01.

Similar articles

Cited by

References

    1. Lin P.W., Stoll B.J. Necrotising enterocolitis. Lancet. 2006;368:1271–1283. doi: 10.1016/S0140-6736(06)69525-1. - DOI - PubMed
    1. Duchon J., Barbian M.E., Denning P.W. Necrotizing Enterocolitis. Clin. Perinatol. 2021;48:229–250. doi: 10.1016/j.clp.2021.03.002. - DOI - PubMed
    1. Dominguez K.M., Moss R.L. Necrotizing enterocolitis. Clin. Perinatol. 2012;39:387–401. doi: 10.1016/j.clp.2012.04.011. - DOI - PubMed
    1. Hunter C.J., Upperman J.S., Ford H.R., Camerini V. Understanding the susceptibility of the premature infant to necrotizing enterocolitis (NEC) Pediatr. Res. 2008;63:117–123. doi: 10.1203/PDR.0b013e31815ed64c. - DOI - PubMed
    1. Alganabi M., Lee C., Bindi E., Li B., Pierro A. Recent advances in understanding necrotizing enterocolitis. F1000Res. 2019;8:107. doi: 10.12688/f1000research.17228.1. - DOI - PMC - PubMed

Publication types